Valuation: Catalyst Pharmaceuticals, Inc.

Market Cap 3.85B 3.43B 3.2B 2.91B 5.5B 371B 5.55B 38.69B 14.99B 189B 14.47B 14.16B 608B P/E 2024
15.9x
P/E 2025 13.9x
Enterprise Value 3.15B 2.8B 2.61B 2.38B 4.49B 303B 4.53B 31.6B 12.24B 155B 11.82B 11.56B 497B EV / Sales 2024
4.02x
EV / Sales 2025 3.67x
Free-Float
99.94%
Yield 2024 *
-
Yield 2025 -
1 day+0.03%
3 months+0.13%
6 months+27.54%
Current year+34.92%
Current year 22.13
Extreme 22.13
32.56
1 year 19.9
Extreme 19.9
32.56
3 years 11.89
Extreme 11.89
32.56
5 years 5.24
Extreme 5.24
32.56
10 years 0.94
Extreme 0.9414
32.56
Manager TitleAgeSince
Chief Executive Officer 65 2023-12-31
Director of Finance/CFO 55 2023-12-31
Chief Tech/Sci/R&D Officer 62 2025-05-31
Director TitleAgeSince
Director/Board Member 48 2026-07-14
Director/Board Member - 2026-07-14
Director/Board Member - 2026-07-14
Date Insider Type Main position Quantity % Market Cap. Importance
7/15/26 Issuer sale

Director

-63,583 0.0519%
7/15/26 Issuer sale

Director

-130,857 0.1069%
7/15/26 Issuer sale

Executive/Senior Manager

-1,051,183 0.8587%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%-.--%+51.10%+160.46% 3.85B
-0.61%-3.43%+36.07%+115.04% 1,019B
-1.02%-5.60%+35.72%+64.63% 617B
+1.11%-0.58%+12.36%+77.95% 464B
+0.34%-3.01%+61.79%+41.24% 356B
-0.95%-4.05%+20.54%+41.71% 333B
-1.46%-2.89%+10.57%+32.81% 267B
-1.35%-5.43%-6.17%+8.98% 244B
-1.04%-2.79%+35.30%+51.84% 218B
-1.87%-4.10%+28.44%+93.66% 179B
Average -0.68%-3.19%+28.57%+68.83% 370.1B
Weighted average by Cap. -0.60%-3.53%+29.10%+70.66%

Financials

2024 2025
Net sales 492M 437M 408M 372M 701M 47.27B 708M 4.93B 1.91B 24.17B 1.85B 1.81B 77.56B 589M 523M 488M 445M 840M 56.62B 847M 5.91B 2.29B 28.95B 2.21B 2.16B 92.9B
Net income 164M 146M 136M 124M 234M 15.76B 236M 1.64B 637M 8.05B 615M 602M 25.85B 214M 190M 178M 162M 306M 20.6B 308M 2.15B 833M 10.53B 805M 787M 33.8B
Net Debt -514M -457M -427M -389M -733M -49.45B -740M -5.16B -2B -25.28B -1.93B -1.89B -81.13B -706M -628M -586M -534M -1.01B -67.91B -1.02B -7.09B -2.75B -34.71B -2.65B -2.59B -111B
Logo Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Employees
182
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. CPRX Stock